Broker Recommendation 證券行薦股 20221228

*One Stock Before the Bell*

*Thermo Fisher Scientific (NYSE: TMO)*
$545.44 (-18.25% YTD)

Thermo Fisher sells scientific instruments and supplies to biotech and pharma firms. It has a *diverse revenue stream*, with 4 different business segments, including life sciences solutions, analytical instruments, diagnostics, and laboratory products, which make up 49.72% of revenue. TMO should benefit from *higher demand for its instruments as chronic and infectious diseases become increasingly prevalent*.

TMO\'s *Q3 revenue* grew by 14.4% YoY. It also recently *acquired clinical research services company PPD for $17.4B* and has *bought back roughly $4B worth of shares*. TMO has *beaten annual EPS estimates for 18 consecutive years since 2004*. Its diversified business and global reach should *help the firm withstand a recession*. The stock appears reasonably valued at a *blended forward P/E ratio of 23.6x*, a *7% discount* to industry peers.